Results 221 to 230 of about 1,224,328 (298)

Operationalizing BioSSbD: A safe‐and‐sustainable‐by‐design framework for biorefineries

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Biorefineries are central to the transition toward a circular bioeconomy; however, their increasing scale and technological heterogeneity, and the integration of biological, chemical, and thermochemical processes introduce complex challenges related to safety, sustainability, and operational reliability. Existing Safe‐and‐Sustainable‐by‐Design
Fernando Ramonet
wiley   +1 more source

Establishing organizational AI governance in healthcare: a case study in Canada. [PDF]

NPJ Digit Med
Kim JY, Hasan A, Kueper J, Tang T, Hayes C, Fine B, Balu S, Sendak M.   +7 more
europepmc   +1 more source

Driving continuous improvement of sustainability certification for industrial biobased systems through comprehensive sustainability requirements

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Existing monitoring frameworks for sustainability certification schemes and labels (CSLs) have largely prioritised environmental aspects, while the social and economic pillars of sustainability remain comparatively underdeveloped. Also, dedicated circularity requirements tailored to biobased systems are still largely lacking, despite being ...
Iris Vural Gursel, Heleen Ballemans, Heike Axmann, Lesly Garcia‐Chavez, Marta Rodriguez‐Illera, Laura Väyrynen   +5 more
wiley   +1 more source

The need to strengthen laboratory leadership, systems, and networks to enhance outbreak detection and resilience in Africa: proceedings of a regional workshop. [PDF]

BMC Proc
Onywera H, Njouom R, Wanjohi DW, Mushumbusi JPC, Moindze A, Kebede A, Ayitewala A, Mwafulango AE, von Gottberg A, Tanui CK, Shikaseba E, Moosa F, Koukouikila-Koussounda F, Guindo I, Ssewanyana I, Bitilinyu-Bangoh J, Nyandwi J, Ndlangisa KM, Koné KM, du Plessis M, Nyenje ME, Diagne MM, Mayet NT, Dereje N, Keita NY, Bonkoungou OJI, Mbala P, Akil-Bandali P, Essomba RG, Niama RF, Chilengi R, Mwangi S, Barro S, Moyo S, Nabadda SN, Maruta T, Muyigi T, Bitoungui VJN, Ahmad U, Chibabhai V, Mokaya WK, Tadjidine Y, Tessema SK, Kaseya J, Tebeje YK.   +44 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Operationalizing the EU AI Act in a comprehensive cancer center through an institutional governance framework. [PDF]

NPJ Digit Med
Gehin W, Faivre JC, Bibault JE, Thiery Y, Deon S, Desandes E, Lambert A, Baudin A, Schoumacker M, Eschwege P, Supiot S, Perennec T, Peiffert D.   +12 more
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Integrating Food Safety, Nutrition Security, and Sustainability Indicators for Food System Monitoring in Low- and Middle-Income Countries: A Structured Methodological Review and Framework Development Study. [PDF]

Foods
Hanna-Wakim L, Sacre Y, Hoteit M.
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

The impact of management practices and industry 4.0 technologies on supply chain sustainability: A systematic review. [PDF]

Heliyon
Al-Okaily M, Younis H, Al-Okaily A.
europepmc   +1 more source